Truist analyst Gregory Renza raised the firm’s price target on Gilead (GILD) to $155 from $152 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm is looking for its management commentary on Yeztugo launch strategy and payer access dynamics in U.S./EU markets and any anito-cel launch preparation updates ahead of the December 23, 2026 PDUFA, Truist added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GILD:
Disclaimer & DisclosureReport an Issue
-1024x683.jpg "Florida Roads Become a Battleground for Illegal Immigration")
-1024x768.jpg "Red Snapper Used as Cudgel by Fed Judge")
